U.S. IVD Instruments Market to Hit USD 18.77B by 2035

Market Outlook

By 2035, the U.S. IVD Instruments Market is expected to reach approximately USD 18.77 billion, expanding at a CAGR of 7.30% during the forecast period 2026–2035. The market is estimated at USD 9.28 billion in 2025, with historical analysis covering 2021–2024. Market values in this report are expressed in USD billions.

The market scope covers instruments and analyzer platforms used for in vitro diagnostic testing across central laboratories, hospital laboratories, reference laboratories, physician offices, emergency and urgent care settings, specialty laboratories, blood banks, public health laboratories, and selected near-patient environments. It includes clinical chemistry analyzers, immunoassay systems, integrated chemistry-immunoassay platforms, hematology analyzers, coagulation systems, molecular diagnostic instruments, microbiology systems, urinalysis instruments, point-of-care analyzers, automated sample-processing systems, and instrument-linked laboratory automation. Stand-alone reagents, consumables, testing services, and research-use-only equipment without a clinical diagnostic use are excluded from the core market calculation.

The U.S. market is entering a new analyzer replacement cycle centered less on incremental analytical performance and more on labor productivity, testing consolidation, automation, turnaround-time predictability, menu breadth, connectivity, and network standardization. Laboratory directors increasingly evaluate analyzers as operational infrastructure rather than individual pieces of diagnostic equipment. Instruments that eliminate manual specimen handling, reduce repeat testing, consolidate chemistry and immunoassay workloads, automate quality-control processes, and allow standardized deployment across multiple hospital sites are therefore capturing a greater share of capital budgets.

Clinical demand remains structurally strong. The U.S. has approximately 320,000 CLIA-regulated laboratory entities, while the country’s healthcare infrastructure includes around 6,100 hospitals and more than 907,000 staffed hospital beds. Diagnostic intensity is also increasing as the population ages and chronic disease management becomes more laboratory dependent. More than 61 million Americans were aged 65 years or older in 2024, while approximately 40.1 million people were living with diabetes in 2023. Cancer diagnostics creates another substantial instrument demand pool, with more than 2.04 million new cancer diagnoses estimated in the U.S. during 2025.

The historical market is estimated to have expanded from approximately USD 6.75 billion in 2021 to USD 7.18 billion in 2022, USD 7.81 billion in 2023, USD 8.58 billion in 2024, and USD 9.28 billion in 2025. Early-period growth reflected molecular testing infrastructure deployed during and immediately after the pandemic, followed by normalization toward broader laboratory modernization. More recently, capital spending has shifted toward high-throughput chemistry and immunoassay systems, integrated workcells, molecular syndromic platforms, automated microbiology, hematology and hemostasis upgrades, and networked point-of-care testing.

From 2026 through 2035, growth will increasingly come from replacing fragmented analyzer fleets with scalable platforms capable of serving multiple testing disciplines and care settings. The commercial advantage will favor manufacturers that can combine reliable instrumentation with large assay menus, strong uptime, responsive service, middleware integration, cybersecurity support, automation, and predictable cost-per-reportable-result economics.

Introduction

According to the U.S. IVD Instruments Market Report, diagnostic instruments form the physical operating backbone of modern laboratory medicine. Although reagents generate substantial recurring revenue across the broader IVD industry, instrument selection frequently determines which reagent ecosystem a laboratory uses for many years. As a result, analyzer placements can influence long-term hospital purchasing behavior far beyond the initial equipment value.

The U.S. laboratory environment is unusually attractive for instrument manufacturers because it combines high testing volumes, sophisticated clinical workflows, advanced hospital infrastructure, large independent reference laboratories, strong adoption of molecular diagnostics, and significant demand for high-throughput automation. The installed base spans very different operating environments, from national reference laboratories processing extremely high specimen volumes to regional hospitals requiring integrated chemistry and immunoassay systems and physician offices requiring compact or CLIA-waived analyzers.

Market economics also differ materially from conventional medical capital equipment. Many IVD analyzers are placed using reagent-rental, lease, managed-service, or long-term supply-contract structures rather than straightforward capital purchase models. Consequently, procurement decisions increasingly evaluate the lifetime economics of the complete analyzer ecosystem. Laboratories consider reagent utilization, service expense, calibration frequency, operator intervention, downtime, sample reruns, footprint, connectivity, staffing requirements, and contract flexibility alongside the nominal instrument price.

The market is particularly exposed to laboratory workforce economics. U.S. laboratories are under persistent pressure to produce more results with fewer manual touches. Automation therefore has a direct economic value. A chemistry or immunoassay analyzer that performs automated maintenance, inventory monitoring, sample management, rerun logic, quality-control handling, and remote troubleshooting can create significant savings even when its acquisition price is higher than a less automated alternative.

The regulatory environment remains another defining characteristic. IVD instruments are medical devices and can be subject to FDA premarket and post market requirements depending on risk classification and intended use. Laboratory operations are additionally shaped by CLIA complexity requirements. The policy environment for laboratory-developed tests changed materially after the 2024 FDA rule was vacated by a federal court in March 2025 and the regulation was formally returned to its previous text in September 2025. For instrument manufacturers, this increases the strategic importance of offering flexible platforms that can support both FDA-cleared assays and specialized laboratory workflows without creating excessive validation burden.

Through 2035, the market will increasingly divide between vendors selling instruments and vendors selling diagnostic operating platforms. The latter combine hardware, assays, automation, informatics, remote service, quality management, inventory visibility, and clinical workflow support. This distinction will strongly influence customer retention and competitive share.

Key Market Drivers: What’s Fueling the U.S. IVD Instruments Market Boom?

The first major driver is the immense U.S. diagnostic testing infrastructure. Approximately 320,000 laboratory entities operate under CLIA, creating one of the deepest installed bases of clinical diagnostic systems globally. These sites range from highly complex hospital and molecular laboratories to physician-office laboratories performing waived testing. The diversity of environments creates demand for instruments across every throughput class, from fully automated floor-standing systems to compact benchtop and near-patient analyzers.

A second major driver is the increasing laboratory intensity of chronic disease management. Diabetes alone affects approximately 40.1 million Americans, while more than 115 million adults have prediabetes. Diabetes management drives repeat use of chemistry analyzers, immunoassay platforms, HbA1c systems, renal function testing, lipid testing, urinalysis, and point-of-care glucose and metabolic testing. Similar recurring diagnostic demand comes from cardiovascular disease, chronic kidney disease, thyroid disorders, autoimmune disease, and other conditions requiring longitudinal laboratory monitoring.

The third structural driver is population aging. The U.S. population aged 65 years and older reached approximately 61.2 million in 2024 and represented around 18% of the population. Older patients consume laboratory services at substantially higher intensity because they are more likely to have multiple chronic conditions, undergo surgery, receive prescription drugs requiring monitoring, experience acute hospitalization, and participate in cancer and metabolic screening. This demographic shift increases analyzer utilization without requiring equivalent growth in the number of laboratory sites.

Cancer testing is another important demand accelerator. More than 2.04 million new U.S. cancer diagnoses were expected in 2025. Oncology increasingly depends on pathology, molecular characterization, immunodiagnostics, sequencing, companion diagnostics, and treatment-monitoring assays. This creates instrument demand beyond conventional pathology laboratories and supports molecular diagnostic systems, immunoassay analyzers, automated sample-preparation platforms, flow-based technologies, and sequencing-related clinical workflows.

The fifth driver is hospital laboratory consolidation. Health systems increasingly operate multiple hospitals, outpatient facilities, urgent care centers, and physician groups under common ownership. These organizations are standardizing instrumentation across networks to improve purchasing leverage, result comparability, staff mobility, service management, and inventory control. An analyzer manufacturer that wins a system-wide standardization contract can gain placements across dozens of sites rather than a single laboratory.

A sixth driver is labor scarcity and the rising economic value of automation. Clinical laboratories cannot indefinitely respond to higher specimen volume by adding personnel. Instrument designs are therefore shifting toward greater walkaway time, automated decapping and recapping, intelligent sample routing, auto verification, onboard inventory tracking, continuous reagent loading, automated maintenance, remote diagnostics, and integrated sample management. Laboratories increasingly calculate analyzer ROI in labor hours avoided rather than solely in cost per test.

A seventh growth driver is the transition toward integrated core-laboratory platforms. Historically, chemistry, immunoassay, hematology, coagulation, urinalysis, microbiology, and molecular diagnostics operated as largely separate instrument categories. That model is gradually being replaced by integrated or closely networked workflows. Chemistry and immunoassay consolidation is already well established, while laboratory automation increasingly connects pre-analytical modules, multiple analyzers, sample storage, middleware, and result management.

Point-of-care decentralization provides another growth vector. Emergency departments, intensive care units, operating rooms, urgent care facilities, physician offices, oncology clinics, and ambulatory centers increasingly require diagnostic answers closer to the patient. Blood gas, coagulation, infectious disease, cardiac biomarker, metabolic, hematology, and molecular systems are gradually shifting selected workloads away from centralized laboratories when faster clinical decisions justify the additional per-test cost.

The final major driver is reimbursement-driven productivity. Medicare’s Clinical Laboratory Fee Schedule continues to contain thousands of billable laboratory test codes, and U.S. laboratories operate under constant reimbursement pressure. Instrument manufacturers therefore face a dual requirement: increase diagnostic sophistication while reducing operating cost. Systems capable of improving throughput, reducing reruns, lowering technician intervention, consolidating testing, and increasing uptime can create greater economic value even without higher reimbursement per test.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in IVD instrumentation is increasingly directed toward removing labor rather than merely increasing analytical speed. The most competitive systems are being designed around the concept of the laboratory as an automated production environment in which samples move from accessioning to validated result with minimal manual intervention.

Integrated clinical chemistry and immunoassay platforms are central to this transition. New-generation analyzers provide broader onboard reagent capacity, continuous loading, automated calibration, improved sample routing, and more compact footprints. This is particularly attractive to regional hospitals and community laboratories that require high analytical capability but cannot economically maintain separate instrument islands or large automation tracks.

High-throughput chemistry remains technologically active despite being a mature testing discipline. Next-generation systems are pushing throughput toward thousands of tests per hour while reducing hands-on maintenance. Higher throughput is valuable, but the more important competitive metric is often uninterrupted throughput. Laboratories increasingly prefer instruments that allow reagent loading, maintenance, troubleshooting, and sample prioritization without lengthy stoppages.

Molecular diagnostics is experiencing a parallel shift from single-test or low-volume PCR toward scalable syndromic automation. Modern molecular platforms increasingly combine extraction, amplification, detection, interpretation, and connectivity in integrated cartridges or automated workcells. High-throughput syndromic systems can allow hospital laboratories to retain molecular testing internally while avoiding the manual complexity historically associated with PCR.

Hematology and coagulation instrumentation is also becoming more automated and information rich. Advanced cell-analysis algorithms, automated slide-review workflows, digital morphology, reflex testing, sample rerouting, and middleware-based rules are reducing manual microscopy requirements. Coagulation systems are being designed to support broader assay menus, higher throughput, automated quality management, and greater walkaway operation.

Clinical microbiology is moving toward faster organism identification and susceptibility workflows. Automated blood culture, microbial identification, MALDI-based systems, digital plate imaging, automated incubation, and rapid susceptibility testing can reduce the interval between specimen collection and actionable clinical information. This matters economically because faster microbiology results may influence antibiotic utilization, length of stay, infection-control decisions, and antimicrobial stewardship.

Artificial intelligence is increasingly being embedded at the instrument and workflow level. The highest-value use cases are likely to involve result flagging, digital morphology, image analysis, quality-control prediction, predictive maintenance, instrument scheduling, sample-routing logic, and identification of abnormal patterns requiring human review. Laboratories are more likely to adopt AI when it reduces workload or improves consistency without forcing staff into an additional standalone software environment.

Connectivity has therefore become a product attribute rather than an IT accessory. Instruments are increasingly evaluated on LIS compatibility, middleware performance, remote service capabilities, cybersecurity architecture, quality-control connectivity, cloud-enabled analytics, and fleet-level monitoring. Large health systems increasingly expect enterprise visibility into instruments distributed across multiple hospitals and outpatient facilities.

Segmentation Insights

The U.S. IVD Instruments Market is segmented on the basis of instrument type, diagnostic technology, application, end user, and system configuration and automation level.

By Instrument Type

Clinical Chemistry and Integrated Chemistry-Immunoassay Analyzers

Clinical chemistry and integrated chemistry-immunoassay analyzers represent the largest instrument category by value. These systems form the core of routine hospital laboratory testing and support metabolic panels, renal and liver function, cardiac markers, endocrine testing, therapeutic monitoring, proteins, electrolytes, and a broad range of specialty assays.

Large laboratories increasingly prefer modular systems capable of scaling analytical capacity without changing the fundamental workflow. Community hospitals and regional laboratories, meanwhile, are adopting compact integrated systems that combine chemistry and immunoassay functionality in a single footprint. Replacement demand is being driven by aging installed bases, health-system standardization, staffing pressure, and the economic value of consolidating previously separate analyzer fleets.

Molecular Diagnostic Instruments

Molecular diagnostic systems are among the fastest-growing instrument categories. The segment includes PCR and real-time PCR platforms, automated nucleic-acid extraction and amplification systems, syndromic diagnostic platforms, digital PCR instruments used clinically, and selected sequencing-based diagnostic systems.

The pandemic dramatically expanded U.S. molecular laboratory capacity, but the post-pandemic market is not simply a replacement market for COVID-19 systems. Molecular testing is broadening into respiratory disease, gastrointestinal infection, meningitis and encephalitis, sexually transmitted infections, oncology, transplant monitoring, antimicrobial resistance, and inherited disorders. High-throughput molecular systems are particularly attractive where laboratories can consolidate multiple pathogen panels on one platform.

Hematology and Hemostasis Instruments

Hematology analyzers, digital morphology systems, coagulation analyzers, platelet-function systems, and associated automation represent a durable diagnostic instrument segment. Complete blood counts are among the most routinely ordered laboratory tests, providing substantial baseline instrument utilization.

Growth is increasingly linked to higher automation rather than population growth alone. Advanced analyzers are designed to reduce manual differential counts, improve flagging of abnormal cells, support automated reflex workflows, and integrate digital morphology. Hemostasis instruments are similarly becoming more automated as hospitals manage coagulation monitoring, thrombosis evaluation, surgical patients, and increasingly complex anticoagulation therapy.

Microbiology Instruments

The microbiology instrument segment includes automated blood-culture systems, organism identification platforms, antimicrobial susceptibility systems, MALDI-based microbial identification technologies, incubation systems, digital imaging platforms, and automated microbiology workcells.

The strategic value of microbiology instrumentation is rising because clinical buyers increasingly connect faster organism identification with antimicrobial stewardship. Hospital systems want to reduce unnecessary broad-spectrum antibiotic use and accelerate targeted treatment. Automated microbiology therefore competes not only on analytical accuracy but also on time-to-result and its downstream effect on care delivery.

Urinalysis and Specialty Diagnostic Instruments

Urinalysis analyzers, sediment-analysis systems, electrophoresis platforms, specialty protein analyzers, autoimmune testing systems, and other specialty instruments account for a smaller but stable portion of the market.

Urinalysis is increasingly moving toward integrated chemistry and digital-particle analysis workflows. Specialty instruments can maintain attractive economics where manufacturers combine differentiated assays with a defensible installed base. Consolidation pressure is nevertheless high because laboratories prefer to migrate lower-volume specialty assays onto broader automated platforms when clinically feasible.

Point-of-Care and Near-Patient Diagnostic Instruments

Point-of-care systems are one of the fastest-changing instrument classes. Blood gas analyzers, cardiac biomarker instruments, coagulation systems, molecular analyzers, metabolic analyzers, hematology systems, and other compact platforms are moving diagnostics closer to the patient.

The strongest adoption occurs when turnaround time changes clinical action. Emergency departments, intensive care units, operating rooms, urgent care centers, oncology clinics, physician practices, and ambulatory facilities can justify decentralized instrumentation when waiting for central-laboratory results creates meaningful workflow delay.

By Diagnostic Technology

Clinical Chemistry

Clinical chemistry remains the largest routine technology base because metabolic, renal, hepatic, lipid, electrolyte, protein, and therapeutic-monitoring assays are fundamental to inpatient and outpatient medicine. Instrument replacement is increasingly driven by throughput, sample handling, automation, onboard stability, and system footprint rather than major changes in fundamental chemistry methodology.

Immunoassay

Immunoassay instrumentation supports endocrine, infectious disease, cardiac, fertility, tumor-marker, autoimmune, and other protein-based testing. Chemiluminescence and related automated immunoassay technologies dominate high-throughput laboratories. Integration with chemistry systems remains an important purchasing factor because hospitals increasingly want common sample management and software environments.

Molecular Diagnostics and Nucleic Acid Testing

PCR, multiplex PCR, digital PCR, isothermal technologies, and sequencing-related diagnostic workflows are expected to generate above-market growth. The most commercially attractive instruments will combine a broad menu with minimal hands-on preparation and strong reimbursement relevance.

Hematology, Flow-Based Analysis and Coagulation

Optical, impedance, fluorescence, flow-based, and clot-detection technologies remain essential to hematology and hemostasis laboratories. Growth is being driven by higher-dimensional cellular information, automated digital review, improved abnormal-cell recognition, and integrated workflow management.

Microbiology, Mass Spectrometry and Other Specialty Technologies

Automated culture, microbial mass spectrometry, susceptibility testing, electrophoresis, digital imaging, and specialty optical technologies collectively form an important high-complexity segment. These platforms are more dependent on specialist workflow and therefore tend to be concentrated in larger hospitals, reference laboratories, academic centers, and specialty laboratories.

By Application

Infectious Disease Diagnostics

Infectious disease remains one of the strongest instrument-growth applications. Respiratory, gastrointestinal, bloodstream, sexually transmitted, central nervous system, and healthcare-associated infections support demand across molecular, microbiology, immunoassay, and point-of-care systems.

A significant post-pandemic change is the movement from pathogen-specific testing toward syndromic platforms capable of detecting multiple clinically relevant organisms from one sample. Hospitals value these systems when they shorten isolation decisions, support antimicrobial stewardship, or reduce send-out testing.

Oncology and Precision Diagnostics

Oncology is a premium instrument application driven by the more than two million new U.S. cancer diagnoses occurring annually. Diagnostic workflows increasingly require molecular characterization, immunodiagnostics, sequencing, companion diagnostics, pathology automation, protein biomarkers, and longitudinal treatment monitoring.

Growth will be concentrated in instruments that can support clinically actionable biomarkers while integrating into established laboratory workflows. Oncology also provides an attractive installed-base model because successful instrument placement can lead to recurring high-value assay utilization.

Diabetes, Endocrine and Cardiometabolic Testing

Diabetes and cardiometabolic disease create exceptionally high repeat testing volumes. Chemistry, immunoassay, HbA1c, lipid, renal function, thyroid, cardiac marker, and point-of-care systems all participate in this application area.

The presence of approximately 40.1 million people with diabetes and more than 115 million adults with prediabetes provides a durable diagnostic demand pool. Routine testing volumes make instrument reliability, throughput, and operating cost particularly important.

Hematology and Coagulation Disorders

Complete blood counts, differential analysis, anemia investigation, leukemia evaluation, coagulation studies, D-dimer testing, anticoagulation monitoring, and preoperative testing support continuous instrument utilization. The segment benefits from high test frequency across emergency, inpatient, oncology, surgery, and outpatient medicine.

Renal, Autoimmune and Other Routine Diagnostics

Renal disease, autoimmune disorders, gastrointestinal conditions, reproductive health, toxicology, drug monitoring, urinalysis, and general health screening create diversified analyzer demand. These applications are less dependent on a single disease trend and therefore contribute stability to the market.

By End User

Hospitals and Integrated Health Systems

Hospitals are the largest purchasers of U.S. IVD instruments because they operate high-volume chemistry, immunoassay, hematology, coagulation, microbiology, molecular, transfusion, and point-of-care testing programs. The U.S. hospital system includes approximately 6,100 hospitals and more than 907,000 staffed beds, creating a substantial capital-equipment installed base.

Large health systems increasingly negotiate enterprise agreements covering multiple analyzer classes and facilities. Vendors capable of offering standardization, strong uptime, integrated service, automation, middleware, and multi-site contracting have an advantage in this environment.

Independent and Reference Laboratories

Large independent laboratories operate some of the highest-throughput diagnostic environments in the country. Their purchasing priorities are highly economic: cost per reportable result, continuous operation, instrument utilization, labor efficiency, reagent logistics, and interface reliability.

These laboratories can influence manufacturer product development because their specimen volumes expose performance limitations that smaller laboratories may never encounter. Highly scalable automation and redundancy are essential.

Physician Offices and Outpatient Clinics

Physician-office laboratories use smaller chemistry, immunoassay, hematology, molecular, and waived testing platforms. Ease of use, small footprint, rapid results, low maintenance requirements, and CLIA complexity classification strongly influence purchasing.

As outpatient care expands, manufacturers are designing instruments that deliver central-laboratory-like capability with reduced operator requirements.

Urgent Care, Emergency and Ambulatory Settings

Urgent care centers, emergency departments, surgery centers, infusion centers, and other ambulatory sites are important growth environments for near-patient testing. Cardiac biomarkers, respiratory testing, blood gas, electrolytes, coagulation, and selected molecular tests have clear value where rapid decisions affect patient disposition.

Specialty, Public Health, Blood Bank and Academic Laboratories

Public health laboratories, blood centers, academic medical centers, specialty pathology laboratories, transplant programs, oncology laboratories, and research-intensive clinical facilities represent smaller but technologically important customers. They often adopt high-complexity instrumentation earlier and can influence broader clinical adoption.

By System Configuration and Automation Level

High-Throughput Floor-Standing Systems

High-throughput systems dominate large hospital and reference laboratories. Their value proposition centers on continuous operation, assay-menu depth, large onboard reagent capacity, automated maintenance, redundancy, and high sample throughput.

Modular and Total Laboratory Automation Systems

Modular systems and automated tracks are expected to gain share as laboratories attempt to remove pre-analytical and post-analytical labor. These configurations can connect centrifugation, decapping, aliquoting, analyzers, sample storage, rerouting, and result-management processes.

Benchtop and Mid-Throughput Analyzers

Benchtop instruments serve community hospitals, specialty laboratories, physician offices, and lower-volume testing areas. This segment is benefiting from miniaturization because manufacturers are delivering increasingly sophisticated chemistry, immunoassay, molecular, and hematology capabilities in smaller footprints.

Point-of-Care Platforms

Near-patient platforms prioritize rapid time-to-result, simplified operation, cartridge-based workflows, compact size, and connectivity. Adoption will continue where clinical speed creates a measurable operational advantage.

Digitally Connected and Remote-Managed Instrument Fleets

Connected instruments form an emerging strategic segment spanning all throughput categories. Health systems increasingly want centralized dashboards for uptime, quality control, reagent inventory, service status, utilization, and cybersecurity. Instrument connectivity is therefore becoming an enterprise procurement requirement.

Regional Insights: Where the Market is Growing Fastest

The U.S. IVD Instruments Market is geographically segmented into the South, West, Northeast, and Midwest. Regional demand reflects population scale, hospital density, age structure, laboratory concentration, prevalence of chronic disease, academic medical-center presence, healthcare-system consolidation, and the mix between hospital, reference-laboratory, and outpatient testing.

The South represents the largest regional market in 2025, while the West is projected to record the fastest growth through 2035. The Northeast remains a high-value market for advanced and specialty diagnostics, while the Midwest provides a large installed base for core-laboratory replacement and health-system standardization.

South

The South is estimated to account for approximately USD 3.47 billion of U.S. IVD instrument revenue in 2025, representing the country’s largest regional opportunity. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Arkansas, Louisiana, and Oklahoma, with the District of Columbia included in broader regional healthcare analysis.

Texas is one of the most important individual IVD instrument markets in the country. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large integrated health systems, academic medical centers, cancer programs, transplant centers, pathology networks, and commercial laboratories. Texas combines rapid population growth with a substantial chronic-disease burden, supporting instrument demand across routine chemistry, molecular diagnostics, hematology, microbiology, and outpatient testing.

Florida is equally strategic because of its large and aging population. The state is particularly attractive for chemistry, immunoassay, hematology, oncology testing, infectious disease diagnostics, and physician-office instruments. Florida’s high concentration of Medicare beneficiaries strengthens routine testing volumes and accelerates the need for instruments capable of supporting chronic disease management.

North Carolina has a strong academic, biotechnology, and health-system environment centered around Raleigh-Durham, Charlotte, Winston-Salem, and other clinical hubs. Georgia is supported by Atlanta’s large provider networks, while Tennessee contains major hospital operators and regional diagnostic infrastructure. Virginia and Maryland benefit from large integrated health systems, federal research connections, and sophisticated academic medicine.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia, and Oklahoma have substantial burdens of diabetes, cardiovascular disease, renal disease, and other chronic conditions. These states create significant testing need but also present rural-access and laboratory-workforce constraints. Compact automation and connected near-patient analyzers therefore have particularly strong strategic potential.

By 2035, the Southern IVD instruments market is projected to approach USD 7.05 billion, supported by continued population growth, health-system expansion, laboratory standardization, molecular testing adoption, and movement of diagnostic capacity into outpatient settings.

West

The West is estimated at approximately USD 1.97 billion in 2025 and is expected to record the fastest regional growth through 2035. The region includes California, Washington, Oregon, Nevada, Arizona, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the dominant Western state market and one of the largest individual IVD instrument markets nationally. Its 2024 population exceeded 39 million, creating a very large diagnostic testing base. The state combines academic medical centers, integrated delivery systems, biotechnology clusters, reference laboratories, oncology programs, genomic medicine, and digital-health adoption.

California is particularly important for molecular diagnostics, clinical genomics, high-complexity testing, automation, and connected laboratory infrastructure. Large health systems in the state can influence national purchasing trends because they often evaluate new diagnostic technologies early and deploy them across multi-hospital networks.

Arizona and Nevada are attractive growth markets because of rapid population expansion and older-adult migration. These factors support routine chemistry, endocrine, hematology, cancer, and infectious disease testing. Colorado and Utah have sophisticated integrated healthcare networks and growing technology-intensive laboratory environments.

Washington and Oregon remain important for academic medicine, integrated care, oncology, and molecular diagnostics. Idaho, Montana, Wyoming, Alaska, and Hawaii have smaller populations but create distinct opportunities for compact analyzers, remote instrument management, point-of-care systems, and technologies capable of delivering complex testing without requiring very large central laboratories.

The West could exceed USD 4.30 billion by 2035, with growth supported by molecular diagnostics, clinical genomics, automation, decentralized testing, AI-enabled workflows, and replacement of legacy core-laboratory systems.

Northeast

The Northeast is estimated to represent approximately USD 2.08 billion in 2025. The region includes New York, New Jersey, Pennsylvania, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont.

New York is the largest market in the region and contains a dense network of academic hospitals, large integrated health systems, cancer centers, independent laboratories, and specialty pathology providers. The New York City metropolitan region generates particularly high volumes of complex testing and supports premium analyzer configurations.

Massachusetts is disproportionately important relative to its population because Boston is one of the country’s strongest clusters for academic medicine, biotechnology, precision diagnostics, and clinical research. Massachusetts laboratories frequently operate advanced molecular, immunodiagnostic, genomic, and specialty testing platforms.

Pennsylvania provides a broad mix of academic hospitals, large community systems, reference laboratories, and rural provider networks. New Jersey benefits from population density, pharmaceutical industry presence, proximity to major New York and Philadelphia healthcare markets, and sophisticated diagnostic infrastructure.

Connecticut and Rhode Island remain smaller but technologically mature markets. Maine, New Hampshire, and Vermont create demand for scalable systems that can support lower-volume hospitals without sacrificing analytical menu depth.

The Northeast market is expected to reach approximately USD 3.95 billion by 2035. Growth will be slower than in the West because population expansion is more moderate, but average instrument sophistication and testing complexity will remain high.

Midwest

The Midwest is estimated at approximately USD 1.76 billion in 2025. The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois is the region’s largest diagnostic instrument opportunity, led by Chicago’s academic hospitals, major health systems, community hospitals, and independent laboratories. Ohio has extensive laboratory infrastructure anchored by large tertiary-care and academic institutions. Michigan similarly supports substantial chemistry, hematology, molecular, microbiology, and cancer-testing volumes.

Minnesota is strategically important because of its medical technology heritage and sophisticated healthcare delivery environment. Wisconsin and Indiana provide substantial community-hospital and integrated-network demand, while Missouri has important clinical hubs in St. Louis and Kansas City.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller populations and significant rural healthcare exposure. Their procurement needs favor reliable, compact systems, remote service capabilities, networked point-of-care testing, and analyzers capable of consolidating multiple testing disciplines into a limited laboratory footprint.

The Midwest is projected to reach approximately USD 3.47 billion by 2035. Its growth profile will be driven primarily by installed-base replacement, health-system standardization, automation, and rural laboratory modernization rather than rapid population growth.

Key Market Players

The U.S. IVD Instruments Competitive Landscape is moderately consolidated at the platform level. Large multinational diagnostics companies control substantial installed bases in chemistry, immunoassay, hematology, molecular diagnostics, microbiology, point-of-care testing, and laboratory automation.

Competitive advantage is increasingly determined by the breadth of the complete installed ecosystem. A laboratory evaluating two analytically comparable instruments may ultimately choose based on assay menu, uptime, service response, middleware integration, automation compatibility, reagent logistics, cybersecurity, contract flexibility, and the ability to standardize the same vendor across multiple sites.

Some of the key players in the U.S. IVD Instruments industry include:

Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Beckman Coulter Diagnostics
Sysmex America
Becton, Dickinson and Company
bioMérieux
Cepheid
QuidelOrtho
Thermo Fisher Scientific
QIAGEN
Bio-Rad Laboratories
Hologic
Illumina
Agilent Technologies
Revvity
Werfen
Radiometer
HORIBA Medical
Mindray North America
DiaSorin
Bruker
Sebia
Nova Biomedical
Fujirebio Diagnostics

Roche, Abbott, Siemens Healthineers, and Beckman Coulter remain particularly powerful in automated chemistry and immunoassay because analyzer placements can lock in substantial recurring assay demand. Sysmex has a strong competitive position in hematology and coagulation. Cepheid and QIAGEN are prominent in automated molecular testing, while bioMérieux and BD hold important positions across clinical microbiology.

QuidelOrtho, Radiometer, Nova Biomedical, Abbott, and other suppliers compete across decentralized and point-of-care workflows. Thermo Fisher, Illumina, Agilent, Bio-Rad, Hologic, DiaSorin, Bruker, and specialty manufacturers participate in molecular, genomic, immunodiagnostic, microbiology, mass-spectrometry, quality-control, and specialized laboratory segments.

Over the forecast period, market share will increasingly be influenced by the ability to win enterprise-level standardization agreements rather than individual analyzer placements. Manufacturers that reduce manual labor, demonstrate high system uptime, shorten turnaround time, provide strong service coverage, and offer broad testing menus will be best positioned to protect premium pricing.

Recent Developments

The U.S. IVD instrument market entered a significant analyzer innovation cycle during 2024–2026, particularly in chemistry, immunoassay, coagulation, hematology, molecular testing, and laboratory automation.

In March 2026, Roche received U.S. FDA clearance for the cobas c 703 and cobas ISE neo analytical units for its modular cobas pro environment. The cobas c 703 is designed for throughput of up to approximately 2,000 tests per hour with as many as 70 reagent positions, while the ISE neo can process up to approximately 1,800 tests per hour. The strategic importance is not merely higher throughput; the systems address the U.S. laboratory need for higher capacity with reduced hands-on maintenance.

In March 2025, Beckman Coulter received FDA clearance for the DxC 500i Clinical Analyzer, combining clinical chemistry and immunoassay in a single system. The platform can perform up to approximately 800 chemistry tests per hour and 100 immunoassay tests per hour. The launch reflects strong demand among lower- and medium-volume laboratories for consolidated capabilities previously associated with larger laboratory footprints.

Sysmex expanded its U.S. instrument portfolio in 2025 with FDA clearances covering next-generation hematology and hemostasis systems. The XR-20 automated hematology analyzer received FDA clearance in June 2025, while the CN-6000 automated coagulation analyzer also received clearance during the year. These developments demonstrate continuing investment in automation within testing disciplines that generate substantial routine hospital volume.

QIAGEN received U.S. clearance for the higher-throughput QIAstat-Dx Rise platform in September 2025. The automated molecular system can process up to approximately 160 tests per day across multiple analytical modules while supporting prioritized urgent testing. In March 2026, its cleared menu was broadened further with gastrointestinal panels, allowing respiratory and gastrointestinal syndromic testing to be consolidated on the same automated instrument.

Siemens Healthineers has been advancing integrated automation around its Atellica CI Analyzer. The company’s compact automation architecture is designed to incorporate tasks such as sample management and other pre-analytical functions directly into the analyzer environment. This development is representative of a wider market transition in which automation once limited to major reference laboratories is being redesigned for mid-volume hospital laboratories.

Regulatory developments also materially changed the commercial environment. The FDA’s 2024 laboratory-developed-test final rule was vacated by a federal district court on March 31, 2025. In September 2025, FDA formally restored the relevant IVD regulatory language to its pre-rule wording. For instrument manufacturers, the result maintains an environment in which laboratory-developed workflows remain strategically important, particularly in molecular pathology, oncology, genomics, and specialty testing.

Taken together, these developments show that the next competitive cycle is not centered on one diagnostic technology. It is centered on automating the laboratory, increasing testing capacity without equivalent staffing growth, and creating scalable platforms whose economic value expands as laboratories add assays and consolidate workflows.

Conclusion

The U.S. IVD Instruments Market Size & Share is positioned to expand from approximately USD 9.28 billion in 2025 to USD 18.77 billion by 2035, representing a 7.30% CAGR during 2026–2035.

Demand will remain structurally supported by approximately 320,000 CLIA-regulated laboratory entities, more than 6,000 U.S. hospitals, an aging population, high chronic disease prevalence, growing cancer-testing complexity, and continued migration toward molecular and near-patient diagnostics.

The greatest value creation will not come from simple replacement of legacy analyzers with newer versions of the same equipment. It will come from laboratories redesigning their operating models around integrated chemistry and immunoassay, automated molecular testing, digital hematology, connected microbiology, total laboratory automation, remote instrument management, and strategically deployed point-of-care systems.

Hospitals and laboratory networks will increasingly judge equipment using total operating economics. Instrument price will remain relevant, but procurement decisions will increasingly depend on technician time, instrument uptime, cost per reportable result, service reliability, assay consolidation, turnaround time, footprint, inventory requirements, middleware compatibility, cybersecurity, and the ability to standardize workflows across an enterprise.

Regionally, the South will remain the largest U.S. market due to population scale and health-system expansion. The West will generate the strongest growth through molecular diagnostics, genomics, automation, and connected care. The Northeast will retain its position as one of the most sophisticated markets for high-complexity testing, while the Midwest will provide a large and durable analyzer replacement opportunity.

For manufacturers, investors, laboratories, and healthcare strategists evaluating the market through 2035, the central commercial question is therefore not simply how many analyzers U.S. laboratories will buy. The more important question is which platforms can become the standardized diagnostic infrastructure through which the greatest volume of future testing flows.

Vendors capable of combining analytical quality with automation, broad menus, connectivity, dependable service, health-system contracting, and measurable labor savings will capture the strongest long-term value. In that environment, the instrument becomes more than laboratory hardware: it becomes the anchor for an enduring diagnostic ecosystem.

TABLE OF CONTENT

1. U.S. IVD Instruments Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Instrument and Analyzer Manufacturers
1.6.2. Diagnostic Reagent, Assay and Consumable Suppliers
1.6.3. Laboratory Automation, Component and Technology Suppliers
1.6.4. Hospitals and Integrated Health Systems
1.6.5. Independent and Reference Laboratories
1.6.6. Physician Offices, Urgent Care and Point-of-Care Operators
1.6.7. Group Purchasing Organizations and Diagnostic Distributors
1.6.8. FDA, CMS, CLIA and Clinical Decision-Makers

What this section provides: This section defines the U.S. IVD instruments market boundary, instrument-only revenue scope, methodology, assumptions, stakeholder ecosystem, and data-validation framework so clients understand how analyzer and diagnostic platform revenues are measured and forecast.

2. U.S. IVD Instruments Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Laboratory Analyzer Replacement Cycle Outlook
2.9. Instrument Installed Base and Automation Opportunity Assessment

What this section provides: This section gives decision-makers a concise view of market size, historical development, analyzer replacement trends, automation adoption, competitive intensity, and priority investment opportunities through 2035.

3. U.S. IVD Instruments Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of U.S. Diagnostic Testing Volumes
3.1.2. Rising Chronic Disease and Aging Population Burden
3.1.3. Laboratory Workforce Shortages and Automation Demand
3.1.4. Expansion of Molecular and Syndromic Diagnostic Testing
3.1.5. Hospital and Laboratory Analyzer Replacement Cycles
3.1.6. Growth of Point-of-Care and Decentralized Testing
3.1.7. Health System Laboratory Standardization and Consolidation
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Diagnostic Platforms
3.2.2. Reagent-Rental and Vendor Lock-In Concerns
3.2.3. Laboratory Reimbursement and Margin Pressure
3.2.4. Instrument Interoperability and LIS Integration Complexity
3.2.5. Regulatory and Validation Requirements
3.3. Opportunities and Their Impact Analysis
3.3.1. Total Laboratory Automation Adoption
3.3.2. Integrated Chemistry-Immunoassay Platforms
3.3.3. High-Throughput Molecular Diagnostic Systems
3.3.4. AI-Assisted Digital Hematology and Laboratory Workflows
3.3.5. Automated Microbiology and Rapid Susceptibility Testing
3.3.6. Point-of-Care Molecular and Near-Patient Diagnostics
3.3.7. Remote Instrument Monitoring and Predictive Maintenance
3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Laboratory Workforce Availability
3.4.2. Instrument Cybersecurity and Data Integrity
3.4.3. Hospital Capital Budget Competition
3.4.4. Supply Chain and Critical Component Availability
3.4.5. Managing Multi-Vendor Laboratory Environments
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Laboratory Workflow Economics Analysis
3.7. Hospital and Reference Laboratory Capital Procurement Behavior Analysis
3.8. Cost-per-Reportable-Result Economics
3.9. Analyzer Installed Base and Replacement Cycle Analysis

What this section provides: This section explains the clinical, operational, reimbursement, workforce, technology, and procurement forces shaping U.S. IVD instrument demand and identifies the most important upside opportunities and execution risks.

4. U.S. IVD Instruments Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Laboratory Buyers
4.2.3. Bargaining Power of Component and Reagent Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. IVD Instrument Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Laboratory Digitalization and Connectivity
4.6. Application & Innovation Landscape
4.7. FDA IVD Regulatory Framework Analysis
4.8. CLIA Laboratory Regulatory Environment
4.9. CMS Clinical Laboratory Reimbursement Landscape
4.10. Laboratory-Developed Test Regulatory Environment
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Diagnostic and Public Health Initiatives
4.13. Impact of Escalating Geopolitical and Supply Chain Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Reagent-Rental, Leasing and Managed-Service Contract Economics
4.16. LIS, Middleware and Instrument Connectivity Landscape

What this section provides: This section gives clients a complete view of the U.S. IVD instrument operating environment, including regulation, reimbursement, capital economics, laboratory connectivity, supply chain, pricing, automation, and purchasing dynamics.

5. U.S. IVD Instruments Market – By Instrument Type

5.1. Overview
5.1.1. Segment Share Analysis, By Instrument Type, 2025 & 2035 (%)
5.1.2. Clinical Chemistry and Integrated Chemistry-Immunoassay Analyzers
5.1.3. Molecular Diagnostic Instruments
5.1.4. Hematology and Hemostasis Instruments
5.1.5. Microbiology Instruments
5.1.6. Urinalysis and Specialty Diagnostic Instruments
5.1.7. Point-of-Care and Near-Patient Diagnostic Instruments

What this section provides: This section identifies which IVD instrument categories generate the largest revenue contribution, strongest installed-base replacement opportunity, and fastest platform growth through 2035.

6. U.S. IVD Instruments Market – By Diagnostic Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Diagnostic Technology, 2025 & 2035 (%)
6.1.2. Clinical Chemistry
6.1.3. Immunoassay
6.1.4. Molecular Diagnostics and Nucleic Acid Testing
6.1.5. Hematology, Flow-Based Analysis and Coagulation
6.1.6. Microbiology, Mass Spectrometry and Other Specialty Technologies

What this section provides: This section evaluates the core analytical technologies underlying U.S. IVD instrumentation and identifies where technology migration, automation, assay-menu expansion, and clinical adoption are creating the strongest growth opportunities.

7. U.S. IVD Instruments Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Infectious Disease Diagnostics
7.1.3. Oncology and Precision Diagnostics
7.1.4. Diabetes, Endocrine and Cardiometabolic Testing
7.1.5. Hematology and Coagulation Disorders
7.1.6. Renal, Autoimmune and Other Routine Diagnostics

What this section provides: This section explains instrument demand by clinical use case and helps clients identify applications with strong testing frequency, diagnostic complexity, reimbursement relevance, and analyzer utilization.

8. U.S. IVD Instruments Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals and Integrated Health Systems
8.1.3. Independent and Reference Laboratories
8.1.4. Physician Offices and Outpatient Clinics
8.1.5. Urgent Care, Emergency and Ambulatory Settings
8.1.6. Specialty, Public Health, Blood Bank and Academic Laboratories

What this section provides: This section identifies the customer groups driving instrument placement, analyzer utilization, replacement cycles, automation investment, and enterprise laboratory standardization.

9. U.S. IVD Instruments Market – By System Configuration & Automation Level

9.1. Overview
9.1.1. Segment Share Analysis, By System Configuration & Automation Level, 2025 & 2035 (%)
9.1.2. High-Throughput Floor-Standing Systems
9.1.3. Modular and Total Laboratory Automation Systems
9.1.4. Benchtop and Mid-Throughput Analyzers
9.1.5. Point-of-Care Platforms
9.1.6. Digitally Connected and Remote-Managed Instrument Fleets

What this section provides: This section evaluates how U.S. laboratories are transitioning from isolated analyzers toward scalable automation, integrated workcells, compact platforms, decentralized testing, and digitally managed instrument fleets.

10. U.S. IVD Instruments Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Laboratory Infrastructure and Testing Volume Analysis
10.1.4. Regional Analyzer Installed Base and Replacement Cycle Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Automation and Point-of-Care Adoption Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Instrument Key Manufacturers and Laboratory Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region IVD Instrument Key Manufacturers and Laboratory Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Instrument Key Manufacturers and Laboratory Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Instrument Key Manufacturers and Laboratory Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Instrument Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By System Configuration & Automation Level, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and 50-state analysis, allowing clients to identify analyzer replacement hotspots, high-volume laboratory markets, automation opportunities, molecular diagnostic adoption centers, point-of-care growth pockets, and state-level commercial priorities.

11. U.S. IVD Instruments Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking by Instrument Portfolio
11.4. Installed Base and Laboratory Platform Positioning
11.5. Company Profiles

11.5.1. Roche Diagnostics
11.5.2. Abbott Laboratories
11.5.3. Siemens Healthineers
11.5.4. Beckman Coulter Diagnostics
11.5.5. Sysmex America
11.5.6. Becton, Dickinson and Company
11.5.7. bioMérieux
11.5.8. Cepheid
11.5.9. QuidelOrtho
11.5.10. Thermo Fisher Scientific
11.5.11. QIAGEN
11.5.12. Bio-Rad Laboratories
11.5.13. Hologic
11.5.14. Illumina
11.5.15. Agilent Technologies
11.5.16. Revvity
11.5.17. Werfen
11.5.18. Radiometer
11.5.19. HORIBA Medical
11.5.20. Mindray North America
11.5.21. DiaSorin
11.5.22. Bruker
11.5.23. Sebia
11.5.24. Nova Biomedical
11.5.25. Fujirebio Diagnostics

Note: Each company profile will include company overview, U.S. IVD instrument portfolio, installed-base positioning, assay and reagent ecosystem, laboratory automation capabilities, U.S. market strategy, financial positioning, FDA regulatory updates, partnerships, product launches, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market share visibility, analyzer portfolio positioning, installed-base intelligence, automation capabilities, innovation direction, and strategic insight into major U.S. IVD instrument companies.

12. U.S. IVD Instruments Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. AI-Assisted Laboratory Automation
12.2.2. Next-Generation Integrated Core Laboratory Platforms
12.2.3. High-Throughput Syndromic Molecular Diagnostics
12.2.4. Digital Hematology and Automated Cell Morphology
12.2.5. Automated Microbiology and Rapid Susceptibility Testing
12.2.6. Point-of-Care Molecular Diagnostics
12.2.7. Predictive Maintenance and Remote Instrument Management
12.2.8. Cloud-Connected Laboratory Instrument Fleets
12.3. Emerging Business Trends
12.3.1. Analyzer-as-a-Service Models
12.3.2. Reagent-Rental and Managed Diagnostic Service Expansion
12.3.3. Enterprise Laboratory Vendor Consolidation
12.3.4. Multi-Site Standardization Across Integrated Health Systems
12.3.5. Shift from Capital Equipment to Platform Economics
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Analyzer Replacement Opportunity, 2026–2035
12.7. Future Laboratory Workflow Architecture

What this section provides: This section prepares clients for future analyzer replacement cycles, disruptive automation technologies, evolving laboratory operating models, investment opportunities, and potential market adoption scenarios through 2035.

13. U.S. IVD Instruments Market: Strategic Recommendations

13.1. Recommendations for IVD Instrument Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Independent and Reference Laboratories
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Diagnostic Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Analyzer Placement and Installed-Base Expansion Strategy
13.10. Reagent-Rental and Long-Term Contracting Strategy
13.11. Laboratory Automation Partnership Strategy
13.12. State-Level Commercial Prioritization Strategy

What this section provides: This section converts market intelligence into actionable strategies for analyzer manufacturers, laboratory operators, investors, distributors, and new entrants covering product positioning, installed-base expansion, automation, contracting, and regional commercialization.

14. U.S. IVD Instruments Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Instrument-Only Market Boundary Disclaimer
14.7. Reagent and Consumable Revenue Exclusion Clarification

What this section provides: This section clarifies the report’s market boundary, forecasting assumptions, instrument-only revenue treatment, data-use limitations, legal terms, and exclusions applicable to the U.S. IVD Instruments Market.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Instruments Market: Market Definition and Scope
TABLE 3: U.S. IVD Instruments Market: Research Methodology Framework
TABLE 4: U.S. IVD Instruments Market: Key Assumptions
TABLE 5: U.S. IVD Instruments Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Instruments Market: Stakeholder Analysis
TABLE 7: U.S. IVD Instruments Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Instruments Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Instruments Market: Market Attractiveness Index
TABLE 10: U.S. IVD Instruments Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Instruments Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. IVD Instruments Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. IVD Instruments Market: High-Growth Opportunity Areas
TABLE 14: U.S. IVD Instruments Market: Analyzer Replacement Cycle Outlook
TABLE 15: U.S. IVD Instruments Market: Instrument Installed Base and Automation Opportunity Assessment
TABLE 16: U.S. IVD Instruments Market: Drivers; Impact Analysis
TABLE 17: U.S. IVD Instruments Market: Restraints; Impact Analysis
TABLE 18: U.S. IVD Instruments Market: Opportunities; Impact Analysis
TABLE 19: U.S. IVD Instruments Market: Challenges; Impact Analysis
TABLE 20: U.S. IVD Instruments Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. IVD Instruments Market: Clinical Laboratory Workflow Economics Matrix
TABLE 22: U.S. IVD Instruments Market: Hospital and Reference Laboratory Capital Procurement Behavior Matrix
TABLE 23: U.S. IVD Instruments Market: Cost-per-Reportable-Result Economics
TABLE 24: U.S. IVD Instruments Market: Analyzer Installed Base and Replacement Cycle Analysis
TABLE 25: U.S. IVD Instruments Market: PESTEL Analysis
TABLE 26: U.S. IVD Instruments Market: Porter’s Five Forces Analysis
TABLE 27: U.S. IVD Instruments Market: IVD Instrument Pricing Trend Analysis by Region, 2025–2035
TABLE 28: U.S. IVD Instruments Market: Value Chain Analysis
TABLE 29: U.S. IVD Instruments Market: Supply Chain Analysis
TABLE 30: U.S. IVD Instruments Market: Laboratory Digitalization and Connectivity Impact
TABLE 31: U.S. IVD Instruments Market: Application & Innovation Landscape
TABLE 32: U.S. IVD Instruments Market: FDA IVD Regulatory Framework Analysis
TABLE 33: U.S. IVD Instruments Market: CLIA Laboratory Regulatory Environment
TABLE 34: U.S. IVD Instruments Market: CMS Clinical Laboratory Reimbursement Landscape
TABLE 35: U.S. IVD Instruments Market: Laboratory-Developed Test Regulatory Environment
TABLE 36: U.S. IVD Instruments Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. IVD Instruments Market: Government Diagnostic and Public Health Initiatives
TABLE 38: U.S. IVD Instruments Market: Impact of Escalating Geopolitical and Supply Chain Tensions
TABLE 39: U.S. IVD Instruments Market: Hospital Value Analysis Committee Decision Framework
TABLE 40: U.S. IVD Instruments Market: Reagent-Rental, Leasing and Managed-Service Contract Economics
TABLE 41: U.S. IVD Instruments Market: LIS, Middleware and Instrument Connectivity Landscape
TABLE 42: U.S. IVD Instruments Market: Instrument Type Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Instrument Type
TABLE 44: U.S. IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 45: U.S. IVD Instruments Market: Segment Share Analysis, by Instrument Type, 2025 & 2035 (%)
TABLE 46: U.S. IVD Instruments Market: Clinical Chemistry and Integrated Chemistry-Immunoassay Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. IVD Instruments Market: Molecular Diagnostic Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. IVD Instruments Market: Hematology and Hemostasis Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. IVD Instruments Market: Microbiology Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. IVD Instruments Market: Urinalysis and Specialty Diagnostic Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. IVD Instruments Market: Point-of-Care and Near-Patient Diagnostic Instruments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. IVD Instruments Market: Diagnostic Technology Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by Diagnostic Technology
TABLE 54: U.S. IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 55: U.S. IVD Instruments Market: Segment Share Analysis, by Diagnostic Technology, 2025 & 2035 (%)
TABLE 56: U.S. IVD Instruments Market: Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. IVD Instruments Market: Immunoassay Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. IVD Instruments Market: Molecular Diagnostics and Nucleic Acid Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. IVD Instruments Market: Hematology, Flow-Based Analysis and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. IVD Instruments Market: Microbiology, Mass Spectrometry and Other Specialty Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. IVD Instruments Market: Application Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Application
TABLE 63: U.S. IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 64: U.S. IVD Instruments Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 65: U.S. IVD Instruments Market: Infectious Disease Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. IVD Instruments Market: Oncology and Precision Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. IVD Instruments Market: Diabetes, Endocrine and Cardiometabolic Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. IVD Instruments Market: Hematology and Coagulation Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. IVD Instruments Market: Renal, Autoimmune and Other Routine Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. IVD Instruments Market: End User Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by End User
TABLE 72: U.S. IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 73: U.S. IVD Instruments Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 74: U.S. IVD Instruments Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. IVD Instruments Market: Independent and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. IVD Instruments Market: Physician Offices and Outpatient Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. IVD Instruments Market: Urgent Care, Emergency and Ambulatory Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. IVD Instruments Market: Specialty, Public Health, Blood Bank and Academic Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. IVD Instruments Market: System Configuration & Automation Level Snapshot, 2025
TABLE 80: Segment Dashboard; Definition and Scope, by System Configuration & Automation Level
TABLE 81: U.S. IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 82: U.S. IVD Instruments Market: Segment Share Analysis, by System Configuration & Automation Level, 2025 & 2035 (%)
TABLE 83: U.S. IVD Instruments Market: High-Throughput Floor-Standing Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. IVD Instruments Market: Modular and Total Laboratory Automation Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. IVD Instruments Market: Benchtop and Mid-Throughput Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. IVD Instruments Market: Point-of-Care Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. IVD Instruments Market: Digitally Connected and Remote-Managed Instrument Fleets Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. IVD Instruments Market: Regional Snapshot, 2025
TABLE 89: Segment Dashboard; Definition and Scope, by Region
TABLE 90: U.S. IVD Instruments Market, by Region, 2021–2035 (US$ Billion)
TABLE 91: U.S. IVD Instruments Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 92: U.S. IVD Instruments Market: Regional Laboratory Infrastructure and Testing Volume Analysis
TABLE 93: U.S. IVD Instruments Market: Regional Analyzer Installed Base and Replacement Cycle Analysis
TABLE 94: U.S. IVD Instruments Market: Regional Reimbursement and Procurement Dynamics
TABLE 95: U.S. IVD Instruments Market: Regional Automation and Point-of-Care Adoption Analysis
TABLE 96: West Region U.S. IVD Instruments Market: Regional Overview and Trends
TABLE 97: West Region U.S. IVD Instruments Market: Key Manufacturers and Laboratory Procurement Ecosystem
TABLE 98: West Region U.S. IVD Instruments Market, by State, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 101: West Region U.S. IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 102: West Region U.S. IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 104: California IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 105: California IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 106: California IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 107: California IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: California IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 109: Washington IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 110: Washington IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 111: Washington IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Washington IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Washington IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 114: Arizona IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 115: Arizona IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 116: Arizona IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 117: Arizona IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: Arizona IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 119: Colorado IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 120: Colorado IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 121: Colorado IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 122: Colorado IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 123: Colorado IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 124: Oregon IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 125: Oregon IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 126: Oregon IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 127: Oregon IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Oregon IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 129: Utah IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 130: Utah IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 131: Utah IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: Utah IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Utah IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 134: Nevada IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 135: Nevada IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 136: Nevada IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: Nevada IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Nevada IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 139: New Mexico IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 140: New Mexico IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 141: New Mexico IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 142: New Mexico IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: New Mexico IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 144: Idaho IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 145: Idaho IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 146: Idaho IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Idaho IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Idaho IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 149: Montana IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 150: Montana IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 151: Montana IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: Montana IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Montana IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 154: Wyoming IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 155: Wyoming IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 156: Wyoming IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 157: Wyoming IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 158: Wyoming IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 159: Alaska IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 160: Alaska IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 161: Alaska IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 162: Alaska IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 163: Alaska IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 164: Hawaii IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 165: Hawaii IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 166: Hawaii IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 167: Hawaii IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 168: Hawaii IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. IVD Instruments Market: Regional Overview and Trends
TABLE 170: Northeast Region U.S. IVD Instruments Market: Key Manufacturers and Laboratory Procurement Ecosystem
TABLE 171: Northeast Region U.S. IVD Instruments Market, by State, 2021–2035 (US$ Billion)
TABLE 172: Northeast Region U.S. IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 173: Northeast Region U.S. IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 174: Northeast Region U.S. IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: Northeast Region U.S. IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: Northeast Region U.S. IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 177: New York IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 178: New York IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 179: New York IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 180: New York IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: New York IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 182: Massachusetts IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 183: Massachusetts IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 184: Massachusetts IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 185: Massachusetts IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 186: Massachusetts IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 187: New Jersey IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 188: New Jersey IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 189: New Jersey IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 190: New Jersey IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: New Jersey IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 192: Pennsylvania IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 193: Pennsylvania IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 194: Pennsylvania IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 195: Pennsylvania IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Pennsylvania IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 197: Connecticut IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 198: Connecticut IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 199: Connecticut IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 200: Connecticut IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 201: Connecticut IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 202: Maine IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 203: Maine IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 204: Maine IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 205: Maine IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: Maine IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 207: Vermont IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 208: Vermont IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 209: Vermont IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: Vermont IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: Vermont IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 212: New Hampshire IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 213: New Hampshire IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 214: New Hampshire IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 215: New Hampshire IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 216: New Hampshire IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 217: Rhode Island IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 218: Rhode Island IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 219: Rhode Island IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 220: Rhode Island IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 221: Rhode Island IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 222: Delaware IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 223: Delaware IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 224: Delaware IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 225: Delaware IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 226: Delaware IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. IVD Instruments Market: Regional Overview and Trends
TABLE 228: South Region U.S. IVD Instruments Market: Key Manufacturers and Laboratory Procurement Ecosystem
TABLE 229: South Region U.S. IVD Instruments Market, by State, 2021–2035 (US$ Billion)
TABLE 230: South Region U.S. IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 231: South Region U.S. IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 232: South Region U.S. IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 233: South Region U.S. IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: South Region U.S. IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 235: Texas IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 236: Texas IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 237: Texas IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: Texas IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: Texas IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 240: Florida IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 241: Florida IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 242: Florida IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 243: Florida IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: Florida IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 245: Georgia IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 246: Georgia IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 247: Georgia IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 248: Georgia IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 249: Georgia IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 250: North Carolina IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 251: North Carolina IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 252: North Carolina IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 253: North Carolina IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: North Carolina IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 255: Tennessee IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 256: Tennessee IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 257: Tennessee IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 258: Tennessee IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Tennessee IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 260: South Carolina IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 261: South Carolina IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 262: South Carolina IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 263: South Carolina IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 264: South Carolina IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 265: Alabama IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 266: Alabama IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 267: Alabama IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 268: Alabama IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 269: Alabama IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 270: Mississippi IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 271: Mississippi IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 272: Mississippi IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 273: Mississippi IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 274: Mississippi IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 275: Louisiana IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 276: Louisiana IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 277: Louisiana IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 278: Louisiana IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Louisiana IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 280: Arkansas IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 281: Arkansas IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 282: Arkansas IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 283: Arkansas IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 284: Arkansas IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 285: Kentucky IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 286: Kentucky IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 287: Kentucky IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 288: Kentucky IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Kentucky IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 290: Oklahoma IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 291: Oklahoma IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 292: Oklahoma IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: Oklahoma IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: Oklahoma IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 295: Virginia IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 296: Virginia IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 297: Virginia IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 298: Virginia IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 299: Virginia IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 300: Maryland IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 301: Maryland IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 302: Maryland IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 303: Maryland IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 304: Maryland IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 305: West Virginia IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 306: West Virginia IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 307: West Virginia IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 308: West Virginia IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 309: West Virginia IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. IVD Instruments Market: Regional Overview and Trends
TABLE 311: Midwest Region U.S. IVD Instruments Market: Key Manufacturers and Laboratory Procurement Ecosystem
TABLE 312: Midwest Region U.S. IVD Instruments Market, by State, 2021–2035 (US$ Billion)
TABLE 313: Midwest Region U.S. IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 314: Midwest Region U.S. IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 315: Midwest Region U.S. IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 316: Midwest Region U.S. IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Midwest Region U.S. IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 318: Illinois IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 319: Illinois IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 320: Illinois IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 321: Illinois IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: Illinois IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 323: Ohio IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 324: Ohio IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 325: Ohio IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 326: Ohio IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 327: Ohio IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 328: Michigan IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 329: Michigan IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 330: Michigan IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 331: Michigan IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 332: Michigan IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 333: Minnesota IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 334: Minnesota IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 335: Minnesota IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 336: Minnesota IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 337: Minnesota IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 338: Indiana IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 339: Indiana IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 340: Indiana IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 341: Indiana IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 342: Indiana IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 343: Wisconsin IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 344: Wisconsin IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 345: Wisconsin IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 346: Wisconsin IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 347: Wisconsin IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 348: Missouri IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 349: Missouri IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 350: Missouri IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 351: Missouri IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 352: Missouri IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 353: Iowa IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 354: Iowa IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 355: Iowa IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 356: Iowa IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 357: Iowa IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 358: Kansas IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 359: Kansas IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 360: Kansas IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 361: Kansas IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 362: Kansas IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 363: Nebraska IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 364: Nebraska IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 365: Nebraska IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 366: Nebraska IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 367: Nebraska IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 368: North Dakota IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 369: North Dakota IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 370: North Dakota IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 371: North Dakota IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 372: North Dakota IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 373: South Dakota IVD Instruments Market, by Instrument Type, 2021–2035 (US$ Billion)
TABLE 374: South Dakota IVD Instruments Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 375: South Dakota IVD Instruments Market, by Application, 2021–2035 (US$ Billion)
TABLE 376: South Dakota IVD Instruments Market, by End User, 2021–2035 (US$ Billion)
TABLE 377: South Dakota IVD Instruments Market, by System Configuration & Automation Level, 2021–2035 (US$ Billion)
TABLE 378: U.S. IVD Instruments Market: Competitive Landscape Snapshot, 2025
TABLE 379: U.S. IVD Instruments Market: Key Company Market Share Analysis, 2025
TABLE 380: U.S. IVD Instruments Market: Company Positioning Matrix
TABLE 381: U.S. IVD Instruments Market: Competitive Benchmarking by Instrument Portfolio
TABLE 382: U.S. IVD Instruments Market: Installed Base and Laboratory Platform Positioning
TABLE 383: U.S. IVD Instruments Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 384: Roche Diagnostics: Company Profile
TABLE 385: Abbott Laboratories: Company Profile
TABLE 386: Siemens Healthineers: Company Profile
TABLE 387: Beckman Coulter Diagnostics: Company Profile
TABLE 388: Sysmex America: Company Profile
TABLE 389: Becton, Dickinson and Company: Company Profile
TABLE 390: bioMérieux: Company Profile
TABLE 391: Cepheid: Company Profile
TABLE 392: QuidelOrtho: Company Profile
TABLE 393: Thermo Fisher Scientific: Company Profile
TABLE 394: QIAGEN: Company Profile
TABLE 395: Bio-Rad Laboratories: Company Profile
TABLE 396: Hologic: Company Profile
TABLE 397: Illumina: Company Profile
TABLE 398: Agilent Technologies: Company Profile
TABLE 399: Revvity: Company Profile
TABLE 400: Werfen: Company Profile
TABLE 401: Radiometer: Company Profile
TABLE 402: HORIBA Medical: Company Profile
TABLE 403: Mindray North America: Company Profile
TABLE 404: DiaSorin: Company Profile
TABLE 405: Bruker: Company Profile
TABLE 406: Sebia: Company Profile
TABLE 407: Nova Biomedical: Company Profile
TABLE 408: Fujirebio Diagnostics: Company Profile
TABLE 409: U.S. IVD Instruments Market: Future Market Scenario Analysis, 2026–2035
TABLE 410: U.S. IVD Instruments Market: Disruptive Technologies Impact Matrix
TABLE 411: U.S. IVD Instruments Market: AI-Assisted Laboratory Automation Opportunity
TABLE 412: U.S. IVD Instruments Market: Integrated Core Laboratory Platform Opportunity
TABLE 413: U.S. IVD Instruments Market: High-Throughput Syndromic Molecular Diagnostics Opportunity
TABLE 414: U.S. IVD Instruments Market: Digital Hematology and Automated Cell Morphology Opportunity
TABLE 415: U.S. IVD Instruments Market: Automated Microbiology and Rapid Susceptibility Testing Opportunity
TABLE 416: U.S. IVD Instruments Market: Point-of-Care Molecular Diagnostics Opportunity
TABLE 417: U.S. IVD Instruments Market: Predictive Maintenance and Remote Instrument Management Opportunity
TABLE 418: U.S. IVD Instruments Market: Emerging Business Trends
TABLE 419: U.S. IVD Instruments Market: Business Opportunities for Startups and Existing Players
TABLE 420: U.S. IVD Instruments Market: Investment Prioritization Matrix
TABLE 421: U.S. IVD Instruments Market: Analyzer Replacement Opportunity, 2026–2035
TABLE 422: U.S. IVD Instruments Market: Future Laboratory Workflow Architecture
TABLE 423: U.S. IVD Instruments Market: Strategic Recommendations for IVD Instrument Manufacturers
TABLE 424: U.S. IVD Instruments Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 425: U.S. IVD Instruments Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 426: U.S. IVD Instruments Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 427: U.S. IVD Instruments Market: Strategic Recommendations for Diagnostic Distributors and Channel Partners
TABLE 428: U.S. IVD Instruments Market: Strategic Recommendations for New Entrants and Startups
TABLE 429: U.S. IVD Instruments Market: Go-to-Market Strategy Considerations
TABLE 430: U.S. IVD Instruments Market: Product Positioning and Portfolio Expansion Guidance
TABLE 431: U.S. IVD Instruments Market: Analyzer Placement and Installed-Base Expansion Strategy
TABLE 432: U.S. IVD Instruments Market: Reagent-Rental and Long-Term Contracting Strategy
TABLE 433: U.S. IVD Instruments Market: Laboratory Automation Partnership Strategy
TABLE 434: U.S. IVD Instruments Market: State-Level Commercial Prioritization Strategy
TABLE 435: U.S. IVD Instruments Market: Scope Limitation
TABLE 436: U.S. IVD Instruments Market: Data Use Limitation
TABLE 437: U.S. IVD Instruments Market: Forecasting Limitation
TABLE 438: U.S. IVD Instruments Market: Legal Disclaimer
TABLE 439: U.S. IVD Instruments Market: Third-Party Data Disclaimer
TABLE 440: U.S. IVD Instruments Market: Instrument-Only Market Boundary Disclaimer
TABLE 441: U.S. IVD Instruments Market: Reagent and Consumable Revenue Exclusion Clarification

List of Figures

FIGURE 1: U.S. IVD Instruments Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Laboratory Workflow Economics Framework
FIGURE 11: Hospital and Reference Laboratory Capital Procurement Decision Framework
FIGURE 12: Cost-per-Reportable-Result Economics Framework
FIGURE 13: Analyzer Installed Base and Replacement Cycle Framework
FIGURE 14: U.S. IVD Instruments Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. IVD Instruments Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. IVD Instruments Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Instrument Type Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Instrument Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Clinical Chemistry and Integrated Chemistry-Immunoassay Analyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Molecular Diagnostic Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Hematology and Hemostasis Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Microbiology Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Urinalysis and Specialty Diagnostic Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Point-of-Care and Near-Patient Diagnostic Instruments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Diagnostic Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Diagnostic Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Immunoassay Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Molecular Diagnostics and Nucleic Acid Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Hematology, Flow-Based Analysis and Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Microbiology, Mass Spectrometry and Other Specialty Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 33: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Infectious Disease Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Oncology and Precision Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Diabetes, Endocrine and Cardiometabolic Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hematology and Coagulation Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Renal, Autoimmune and Other Routine Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 40: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Independent and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Physician Offices and Outpatient Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Urgent Care, Emergency and Ambulatory Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Specialty, Public Health, Blood Bank and Academic Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: System Configuration & Automation Level Segment Market Share Analysis, 2025 & 2035
FIGURE 47: System Configuration & Automation Level Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: High-Throughput Floor-Standing Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Modular and Total Laboratory Automation Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Benchtop and Mid-Throughput Analyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Point-of-Care Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Digitally Connected and Remote-Managed Instrument Fleets Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 54: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Regional Laboratory Infrastructure and Testing Volume Comparison, 2025
FIGURE 56: Regional Analyzer Installed Base and Replacement Opportunity Map
FIGURE 57: West Region U.S. IVD Instruments Market Share and Leading Players, 2025
FIGURE 58: West Region Market Share Analysis by State, 2025
FIGURE 59: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: California IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Washington IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Arizona IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Colorado IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Oregon IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Utah IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Nevada IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Mexico IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Idaho IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Montana IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Wyoming IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Alaska IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Hawaii IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Northeast Region U.S. IVD Instruments Market Share and Leading Players, 2025
FIGURE 74: Northeast Region Market Share Analysis by State, 2025
FIGURE 75: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New York IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Massachusetts IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Jersey IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Pennsylvania IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Connecticut IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Maine IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Vermont IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Hampshire IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Rhode Island IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Delaware IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Region U.S. IVD Instruments Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Florida IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Georgia IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: North Carolina IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Tennessee IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Carolina IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Alabama IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Mississippi IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Louisiana IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Arkansas IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Kentucky IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Oklahoma IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Virginia IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Maryland IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: West Virginia IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Midwest Region U.S. IVD Instruments Market Share and Leading Players, 2025
FIGURE 105: Midwest Region Market Share Analysis by State, 2025
FIGURE 106: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Illinois IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Ohio IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Michigan IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Minnesota IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Indiana IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Wisconsin IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Missouri IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Iowa IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Kansas IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Nebraska IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: North Dakota IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: South Dakota IVD Instruments Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 120: Company Positioning Matrix
FIGURE 121: Key Player IVD Instrument Portfolio Benchmarking
FIGURE 122: Installed Base and Laboratory Platform Positioning
FIGURE 123: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 124: U.S. IVD Instrument Innovation Roadmap
FIGURE 125: AI-Assisted Laboratory Automation Adoption Roadmap
FIGURE 126: Integrated Core Laboratory Platform Opportunity Map
FIGURE 127: High-Throughput Molecular Diagnostics Growth Roadmap
FIGURE 128: Digital Hematology and Automated Morphology Roadmap
FIGURE 129: Automated Microbiology and Rapid Susceptibility Testing Roadmap
FIGURE 130: Point-of-Care Molecular Diagnostics Growth Roadmap
FIGURE 131: Predictive Maintenance and Remote Instrument Management Roadmap
FIGURE 132: Future Market Scenario Analysis, 2026–2035
FIGURE 133: Disruptive Technologies Impact Matrix
FIGURE 134: Emerging Business Trends Matrix
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Analyzer Replacement Opportunity Map, 2026–2035
FIGURE 137: Future Laboratory Workflow Architecture
FIGURE 138: Strategic Growth Roadmap for U.S. IVD Instrument Companies
FIGURE 139: Go-to-Market Strategy Framework
FIGURE 140: Product Positioning and Portfolio Expansion Framework
FIGURE 141: Analyzer Placement and Installed-Base Expansion Framework
FIGURE 142: Reagent-Rental and Long-Term Contracting Framework
FIGURE 143: Laboratory Automation Partnership Framework
FIGURE 144: State-Level Commercial Prioritization Map
FIGURE 145: Report Scope and Disclaimer Framework